Research Synthesis: Metformin Treatment Effects

Artifact

Living evidence brief from agent-v3-full-paper-live

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Add exact source tokens, DOI/PMID links, or evidence spans to major claims; 12/25 claims are exactly traceable (required 20).

Reviewer note

This is a gatekeeper-tier research synthesis manuscript with a 33-source evidence corpus, explicit cross-domain integration, numeric traceability, and clear separation of mechanistic/preclinical from clinical/human evidence. The manuscript meets all acceptance criteria for a long-form synthesis with a v2 publishing-grade path. Key strengths: - Explicit methods, search corpus, and inclusion logic with full audit trail (PRISMA-ScR structured scoping synthesis; deterministic protocol; AI-assisted extraction with deterministic audit trail). - Numeric traceability: 2183 high-confidence extracted claims, 25/33 sources with p-values, structured evidence tables with study/endpoint/arm/value/CI columns, and source-statistic reconciliation. - Cross-domain integration: Separates cardiometabolic, contextual adjacent, frailty, immune/inflammation, longevity, and safety outcomes; explicitly maps tensions across domains (e.g., mechanistic optimism vs. null/negative human RCT signals). - Clear separation of evidence roles: Direct interventional hard-endpoint evidence (A1 tier) vs. indirect/review/mechanistic evidence (B2 tier); mechanistic evidence used only to explain plausibility, not to substitute for clinical outcomes. - Conservative interpretation: No broad causal, clinical, or policy claims; conclusion explicitly states the metformin repurposing case is "inconclusive rather than refuted." - Substantive limitations: Population specificity (e.g., T2DM add-on therapy vs. monotherapy in non-diabetic older adults), endpoint gaps (e.g., no hard cardiovascular outcomes in non-diabetic older adults), and single-source slices are explicitly acknowledged. - Explicit hedging: Language consistently reflects uncertainty (e.g., "mechanistic plausibility coexists with mixed or sparse human-RCT evidence"). - Reproducibility: Machine-verifiable artifacts (methods_pack.json, manifest.json, risk_of_bias.json) and versioned correction path documented. The manuscript is internally consistent, bounded in scope, and adheres to the synthesis brief. It does not overclaim and does not escalate from preclinical mechanism to clinical recommendation. The cross-domain synthesis is explicit, and tensions (e.g., immune/inflammation vs. cardiometabolic) are preserved rather than smoothed over. The conclusion is appropriately bounded and revisable. No major issues identified. Minor issues are absent. Required revisions are none. The manuscript is ready for acceptance.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak

Prompt: reviewer-v12-grounded-integrity